Orforglipron is taken once a day and climbs through six strengths before reaching its maximum. The pattern will look familiar to anyone who has been on a GLP-1 medicine: start low, move up slowly, and let the digestive system adjust at each stage. This article sets out the schedule, the reasoning behind it, and the flexibility that exists within it.
The schedule
Treatment begins at 0.8 mg once daily. After at least 30 days, the dose increases to 2.5 mg, then after at least another 30 days to 5.5 mg. Further increases follow the same monthly minimum interval, to 9 mg, then 14.5 mg, and finally 17.2 mg, which is the maximum dose. Each step depends on how someone is responding and how well they are tolerating the medicine, so the schedule describes the fastest reasonable path rather than a fixed timetable. Taken at the minimum intervals, reaching the top dose takes around five months from the first tablet.
Why it starts so low
The 0.8 mg starting dose is not intended to produce weight loss. Its job is to introduce the medicine gently so the digestive system can adapt, because the nausea, fullness and altered bowel habit that come with this class of drug are far more severe when a full dose arrives without warning. Trials showed side effects were more common at higher starting doses and when increases came too quickly. Treating the first month as a tolerance-building phase, and not judging the medicine on the weight change during it, is the single most useful expectation to set at the outset.
The step up is where the difficulty lives
Side effects on this class of medicine track dose changes rather than total time on treatment. The days following each increase are typically the hardest, and things settle over the following week or two. Knowing this changes how the escalation feels: a difficult few days after moving up is the expected pattern rather than a sign that the medicine is not suiting you. It also means the practical preparations, smaller and plainer meals, attention to fluid and fibre, avoiding the fattiest food for a few days, are worth putting in place before each step rather than in response to it.
The highest dose is not the goal
It is easy to read a six-step schedule as a ladder to be climbed, with 17.2 mg as the finish line. That is the wrong frame. The aim is the lowest dose that delivers the result you need at a level of side effects you find acceptable, and for some people that will be reached well before the top of the range. A dose increase makes sense when appetite control has faded and weight loss has flattened over several weeks at a stable dose. It makes much less sense simply because a month has elapsed. If you are losing weight steadily and comfortably at 9 mg, there is no prize for reaching 17.2 mg.
Going back down is allowed
If an increase proves too difficult, dropping back to the previous dose and staying there longer is a legitimate clinical option rather than a failure. So is pausing an escalation entirely and holding at a dose that is working. The escalation schedule sets out the minimum intervals and the maximum dose; it does not oblige anyone to travel the whole distance. Prescribers make these adjustments routinely, and the alternative, pushing through side effects that are genuinely limiting, is what causes people to stop treatment altogether.
Missed doses
With a daily medicine, a single missed dose is a smaller event than with a weekly injection, and the general principle across daily tablets is to take the next dose at the usual time rather than doubling up to compensate. Because orforglipron clears from the body faster than the weekly injectables, consistency day to day matters, so if missed doses become a pattern rather than an occasional lapse, it is worth mentioning at review. Specific guidance on missed doses will be set out in the UK product information once it is published.
How this compares with other GLP-1 schedules
Six steps is more than most. Mounjaro has six strengths but they are spaced across a wider dose range, and semaglutide products typically use four or five. The direction of travel is the same across all of them: a low introductory dose, monthly minimum intervals, and escalation guided by response and tolerability rather than by the calendar. Anyone who has been through the escalation on an injectable will find the rhythm familiar, with the difference that a daily tablet spreads each dose more evenly rather than concentrating it in the days after a weekly injection.
What the escalation means for judging progress
Because the dose climbs for months, the weight-loss curve tends to be shallow early and steepen later, and this trips people up more than the side effects do. Very little should be expected during the 0.8 mg month, and the meaningful trajectory usually emerges once the middle doses are reached. Trial averages describe 72 weeks of treatment, most of which is spent at a settled dose, so measuring yourself against those figures at week six is comparing two entirely different things. A more useful marker is whether appetite is genuinely reduced at the current dose and whether the trend over several weeks is downward, rather than what the scales say on any given morning.
A note on where this guidance comes from
The schedule above reflects the dosing approved at UK authorisation. Full UK prescribing information will appear in the product's summary of product characteristics, and anyone prescribed orforglipron once it becomes available should follow the instructions given with their own prescription, which take account of their circumstances in a way that no article can. Nothing here is a reason to alter a dose without speaking to a prescriber.
